IP Library Granted Patent US 11,903,956
Granted Patent B2
US 11,903,956 · App. 17/572,021 · Granted Feb 20, 2024

Compositions and products for infectious or inflammatory diseases or conditions

Inventor: Huiru Wang (Willowbrook, IL)
Assignee: B&H BIOTECHNOLOGIES, LLC
A61K31/7008A23K20/142A23K20/147A23L33/10A23L33/17A23L33/175A61K9/0019A61K9/0043A61K9/0095A61K31/198A61K45/06C07C321/14C07H15/12A23V2002/00A61K9/08A61K9/10A61K9/107A61K47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,903,956
App. No.
17/572,021
Granted
Feb 20, 2024
Kind
B2
Abstract

Composition and methods for treating infectious and inflammatory diseases using saccharide based products and therapies. Products can be implemented as a nutritional supplement, a food, a feed, a food additive, a feed additive, a therapeutic product, a rehydration salt, or a rehydration solution. The present disclosure relates generally to the fields of compositions and products containing the compositions, and the use of the compositions or the products for preventing and/or treating infectious or inflammatory diseases or conditions in particular gastrointestinal and respiratory diseases (diarrhea and influenza infections) or inflammatory.

Claims (17)

1. A method for treating an infectious disease, inflammatory disease or infection-relating disease or condition, the method comprising administering an effective amount of a composition to a patient diagnosed with an infectious disease, inflammatory disease or an infection-relating disease or condition, wherein the composition comprises:

(a) about 0.01 mg/mL to about 20 mg/mL of N-acetylneuraminic acid;

(b) about 0.01 mg/mL to about 20 mg/mL of N-acetylneuraminic acid methyl ester; and

(c) about ¼ to about ¾ of the manufacturer's recommended dose of Tamiflu for the treatment of influenza; or

(d) about ¼ to about ¾ of the manufacturer's recommended dose of Enrofloxacin for the treatment of rotavirus infection or diarrhea; or

(e) about ¼ to about ¾ of the manufacturer's recommended dose of Cephradine for the treatment of diarrhea gastroenteritis; and

wherein the infectious disease, inflammatory disease or an infection-relating disease or condition is gastroenteritis, diarrhea, or viral infection caused by influenza or rotavirus.

2. The method of claim 1 , wherein the administration is subcutaneous, topical, oral, intramuscular, intravenous, intraperitoneal, intracavital, or transdermal, or via inhalation.

3. The method of claim 1 , wherein the patient is an animal, wherein the animal is a cow, pig, horse, sheep, goat, llama, cattle, donkey,chicken, duck, goose, turkey, pigeon, a dog, a cat, a rodent, bird, a fish, a shrimp, an oyster, a crustacean, or a mollusk.

4. The method of claim 1 , wherein the patient is a human.

5. A method for treating an infectious disease, inflammatory disease or infection-relating disease or condition with a reduced amount of antibiotic, the method comprising:

administering to a patient diagnosed with an infectious disease, inflammatory disease or an infection-relating disease or condition an effective amount of a composition comprising N-acetylneuraminic acid or N-acetylneuraminic acid and an antibiotic,

wherein the composition comprises an amount of the antibiotic is about 10% to about 75% less than the amount of the antibiotic if the antibiotic had been used alone, and

wherein the infectious disease, inflammatory disease or an infection-relating disease or condition is gastroenteritis, diarrhea, or viral infection caused by influenza or rotavirus.

6. The method of claim 5 , wherein the composition further comprises at least one of:

N-acetylneuraminic acid methyl ester; or

a methionine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2024
From: WANG, HUIRU
To: B & H BIOTECHNOLOGIES, LLC
Reel/Frame 066070/0801 →
Continuity (3)
Division 14775952
Provisional Application 61792984 · Mar 15, 2013
Related Publication 20220211733A1 · Jul 7, 2022